Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...
Alcon's $200M RxSight partnership aims to recapture IOL market share with adjustable presbyopic lenses. RxSight gets 30% ...
Medical Device Network on MSN
Alcon spends up to $200M to co-develop customisable cataract lenses with RxSight
The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for ...
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies ...
Alcon and RxSight announced a nonexclusive collaboration to develop a light-adjustable presbyopia-correcting IOL, according ...
Despite near-term headwinds, RxSight has long-term upside from the Alcon royalty partnership, stronger margins and discounted ...
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Alcon Inc. (NYSE:ALC) is one of the best ...
Milestone includes more than 6 million PCIOL implants worldwide, with PanOptix and Vivity leading globally in trifocal and EDOF IOLs1,* PanOptix delivers outstanding patient satisfaction and freedom ...
TruPlus is designed to increase depth of focus while maintaining the high-quality distance vision surgeons expect from a monofocal IOL1,2 TruPlus demonstrates higher distance image quality across ...
FORT WORTH, Texas--(BUSINESS WIRE)--April 25, 2005--Alcon, Inc., (NYSE:ACL) announced the launch of the AcrySof(R) ReSTOR(R) Intraocular Lens (IOL) at a press conference during the American Society of ...
Alcon ALC recently announced the launch of the Clareon Family of Intraocular Lenses (IOLs) in India. The company’s most advanced platform to date builds on its long legacy of IOL innovation and is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results